Direct Detection of Nucleic Acid Diagnostics
Nanosphere’s technologies, as presented in Verigene^® System and tests, will greatly simplify molecular diagnostic testing, making it accessible to virtually any clinical laboratory. This will allow for localized molecular diagnostic testing and decision-making at the greater than 4,000 hospital-based laboratories in the United States. A similar number of hospital laboratories in the EU and other regions of the globe will benefit similarly by having access to a testing platform that does not require substantial technical and operational expertise.

In the molecular diagnostics market, Nanosphere has developed tests for the following areas:

• Genetics
• Pharmacogenetics
• Infectious Diseases*
• Oncology*

High-sensitivity Protein Diagnostics
Nanosphere's nanoparticle probe technology enables high-sensitivity, multiplexed detection of proteins in clinical samples.  Detection of new and existing protein biomarkers at sensitivity levels 2-3 orders of magnitude higher than existing ELISA-based tests is being explored in several areas: